Adaptimmune Therapeutics plc (NASDAQ:ADAP – Get Free Report) was the recipient of a significant increase in short interest in the month of July. As of July 31st, there was short interest totalling 7,130,000 shares, an increase of 13.2% from the July 15th total of 6,300,000 shares. Based on an average daily volume of 2,030,000 shares, the short-interest ratio is presently 3.5 days.
Analyst Ratings Changes
ADAP has been the subject of several analyst reports. StockNews.com upgraded Adaptimmune Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, August 13th. HC Wainwright reissued a “buy” rating and set a $4.00 price target on shares of Adaptimmune Therapeutics in a report on Tuesday, August 13th. Scotiabank started coverage on shares of Adaptimmune Therapeutics in a report on Thursday, May 30th. They set a “sector outperform” rating and a $3.15 price objective for the company. Finally, Mizuho reduced their target price on Adaptimmune Therapeutics from $9.00 to $3.00 and set a “buy” rating on the stock in a report on Friday, May 17th.
Check Out Our Latest Stock Report on ADAP
Institutional Trading of Adaptimmune Therapeutics
Adaptimmune Therapeutics Trading Down 0.9 %
Shares of NASDAQ ADAP opened at $1.08 on Friday. Adaptimmune Therapeutics has a 1-year low of $0.42 and a 1-year high of $2.05. The company has a 50-day moving average of $1.10 and a two-hundred day moving average of $1.20. The company has a market cap of $266.57 million, a PE ratio of -1.46 and a beta of 2.31.
Adaptimmune Therapeutics (NASDAQ:ADAP – Get Free Report) last posted its quarterly earnings results on Wednesday, May 15th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by ($0.02). The firm had revenue of $5.68 million during the quarter, compared to the consensus estimate of $4.40 million. Adaptimmune Therapeutics had a negative net margin of 890.13% and a negative return on equity of 259.68%. As a group, equities research analysts forecast that Adaptimmune Therapeutics will post -0.55 earnings per share for the current year.
About Adaptimmune Therapeutics
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.
Featured Articles
- Five stocks we like better than Adaptimmune Therapeutics
- Dividend Capture Strategy: What You Need to Know
- Bumble’s Valuation Hits an All-Time Low, Can Its Fortunes Change?
- About the Markup Calculator
- MarketBeat Week in Review – 8/12 – 8/16
- Ride Out The Recession With These Dividend Kings
- JD.com Earnings Surprise: China’s Outlook Better Than Expected
Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.